B
Bull
Bull · 25%TVGN
$1.56
Precio del escenario
$6.890
+0.143 (+2.07%)Al cierre
Loading chart…
- High
- 6.930
- Open
- 6.550
- VWAP
- 6.79
- Vol
- 2.63K
- Mkt Cap
- —
- Low
- 6.550
- Amount
- 17.82K
- EV/EBITDA, TTM
- 0.00
Tevogen Inc., formerly Tevogen Bio Holdings Inc., is a socially integrated healthcare enterprise. The Company leverages artificial intelligence and precision T cell therapy platforms, and engagements with global technology companies to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, its lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology. Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. It is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and insurance solutions for healthcare providers.
AI analysis of Tevogen Bio Holdings Inc (TVGN)
holdTevogen Bio Holdings Inc is not a good buy right now due to its significant financial losses and negative analyst sentiment. The stock has a current price of 6.89, and its forward P/E ratio is 0, indicating no earnings expectations. Additionally, the company has reported a staggering year-to-date change of -62.12%, reflecting ongoing financial struggles.
Métricas de valoración
The current forward P/E ratio for Tevogen Bio Holdings Inc (TVGN) is 0.00, compared to its 5-year average forward P/E of -0.93.
Alphio AI Price Scenarios for TVGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
4.507-29seekingalphaTevogen Bio Holdings Rebrands as Tevogen Inc.
2.007-28NASDAQ.COMBiotech Stocks Surge Following Key Developments
4.506-09NewsfilterTevogen Appoints William Keane as Interim Head of Healthcare Services Initiative
8.505-29NASDAQ.COMSciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
8.505-29NASDAQ.COMTevogen Bio Advances Strategic Acquisition Plans
TVGN FAQ — answered by Alphio AI
Tevogen Inc., formerly Tevogen Bio Holdings Inc., is a socially integrated healthcare enterprise. The Company leverages artificial intelligence and precision T cell therapy platforms, and engagements with global technology companies to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, its lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology. Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. It is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and insurance solutions for healthcare providers. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Tevogen Bio Holdings Inc is not a good buy right now due to its significant financial losses and negative analyst sentiment. The stock has a current price of 6.89, and its forward P/E ratio is 0, indicating no earnings expectations. Additionally, the company has reported a staggering year-to-date change of -62.12%, reflecting ongoing financial struggles.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.